Understanding the methylfolate trap has significant implications for clinical practice and patient management. B12 deficiency does not simply reduce circulating B12 levels—it creates a functional folate deficiency by sealing the metabolic pathway that converts inactive folate into active forms cells can use for DNA synthesis.
This explains a clinically important paradox: patients with B12 deficiency develop megaloblastic anemia and cell division impairments despite normal or even elevated folate intake and stores. The solution requires B12 repletion, not folate supplementation. Giving additional folate to a B12-deficient patient cannot overcome the enzymatic blockade created by methionine synthase dysfunction.
For clinicians, this means recognizing that elevated RBC folate levels in the context of anemia and neurological symptoms should raise suspicion for underlying B12 deficiency rather than reassure. Targeted B12 replacement remains the cornerstone of treatment.
Was this article helpful?
